Health care's 1.8% week was four large caps, not a biotech rally

One 2.2% position in the equal-weight S&P biotech fund AXBI earned more this week than the entire fund. Twist Bioscience, a DNA-synthesis company, rose 31% and added 0.69 percentage points to a book that finished up 0.33%. That is one health-care market: a sleeve small enough to miss, large enough to make the week.

The other is the $43.6 billion State Street Health Care Select Sector SPDR ETF AXLV, which holds the S&P 500 health-care sector. Eli Lilly is 15% of it. The top ten names are 61%. From Friday, September 11, through Friday, September 18, four large cash-generating incumbents carried the fund. Lilly contributed 0.5 percentage points; Johnson & Johnson, AbbVie, and Thermo Fisher Scientific added the next 0.66, more than Lilly. Cap-weighted health care is a pharma balance-sheet position. Equal-weight biotech is a book where a 2.2% sleeve can out-earn the whole fund.

Lilly at 15%, the top ten at 61%

Invesco's equal-weight S&P 500 health-care fund BRSPH gained 1.80%, matching AXLV this week, and it leads by about 6 percentage points year to date. That is the construction choice: AXLV costs 0.08% and concentrates; BRSPH costs 0.40% and spreads the same names evenly.

Lilly closed at $1,153, up 3.3% for the week. On Friday the FDA approved Inluriyo (imlunestrant) plus Verzenio (abemaciclib) for adults with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. In the Phase 3 EMBER-3 trial, the combination doubled median progression-free survival versus Inluriyo alone. Friday's close was flat. CVS Health subtracted 0.12 percentage points from AXLV.

Large-cap pharma followed the same split. The $1.03 billion VanEck Pharmaceutical ETF APPH, 19% Lilly, gained 1.58%. The equal-weight State Street SPDR S&P Pharmaceuticals ETF BXPH fell 0.84%.

Xenon filed in epilepsy and paused in depression

Xenon Pharmaceuticals announced Thursday that it had submitted a new drug application for azetukalner in focal seizures, based on the Phase 2b X-TOLE and Phase 3 X-TOLE2 trials, and that it had voluntarily paused new enrollment in its Phase 3 psychiatry studies. Existing patients in X-NOVA2 (major depressive disorder) and X-CEED (bipolar depression) remain on drug. The company said neuropsychiatric adverse events, including psychosis, had appeared that were not seen in the earlier Phase 2 X-NOVA depression study. It described the pause as temporary and taken in consultation with its data-safety monitoring board.

Chief Medical Officer Christopher Kenney told analysts the epilepsy program that supports the filing carried one psychosis case across both trials. He said the neuropsychiatric events, in epilepsy and in psychiatry, have been short in duration and reversible, without long-term sequelae. That is a different fact from a class-wide signal. The NDA stayed on the calendar; psychiatry enrollment stopped. The psychiatry studies use a 20-milligram dose. Chief Executive Ian Mortimer said Xenon will use the pause to adjust dosing, which it believes will improve tolerability, over the coming months, and has notified the FDA.

X-NOVA2 had reached about 80% of its 450-patient target, or about 360 patients, which the company said is still powered to show a clinically meaningful change on the HAM-D17 depression scale. Xenon will finish the six-week dosing period for patients already enrolled and now expects X-NOVA2 topline data in the first quarter of 2027. Two additional Phase 3 epilepsy studies, X-TOLE3 in focal seizures and X-ACKT in primary generalized tonic-clonic seizures, continue to enroll.

Xenon fell 31% on Friday to $39.75, a 32% decline for the week, on 17.9 million shares against an average of about 1.2 million, about 15 times normal turnover. The NDA is real. The psychiatry expansion is what the session priced. In AIBB, cap-weighted toward Vertex, Amgen, and Gilead, Xenon is a 0.38% weight and subtracted 0.12 percentage points. The fund gained 0.81%. Natera, Illumina, Gilead, and Moderna added 1.45 percentage points combined.

On Wednesday Twist said it would supply antibody characterization data to Eli Lilly's TuneLab discovery platform. In AXBI, Iovance Biotherapeutics, Moderna, and Natera, which closed at $369.39 near a 52-week high, filled out the plus side. Arrowhead Pharmaceuticals, Scholar Rock, and Praxis Precision Medicines took enough off to leave the equal-weight book nearly unchanged. BIDNA rose 4.65%. Twist, a 6.3% position, accounted for 42% of that move.

Definium Therapeutics reported Monday that the Phase 3 Panorama study of DT120, a 100-microgram orally disintegrating lysergide tablet, met its primary endpoint in generalized anxiety disorder. At week 12, HAM-A scores fell 9.8 points on the 100-microgram dose versus 4.7 points on placebo, a 5.1-point placebo-adjusted difference, p<0.0001. Panorama is the company's second positive Phase 3 trial in GAD. Definium has scheduled a pre-NDA meeting with the FDA for the fourth quarter of 2026 and has said it expects to file in the first half of 2027; any U.S. approval would still require DEA rescheduling before marketing.

The result is a hit on the endpoint the protocol named. DFTX rose 3.5% on Monday and fell 8.5% on Tuesday. It closed the week at $38.81, down 0.2%. That is what a second confirmatory trial looks like when the first one already did the rerating. Definium is a 2.7% position in BXPH and is not among the largest holdings in AXBI.

Ultragenyx received full FDA approval Thursday for FAYUVI (rebisufligene etisparvovec-hopf), also known as UX111, the first FDA-approved gene therapy for pediatric mucopolysaccharidosis type IIIA, or Sanfilippo syndrome Type A. Shares jumped 12.6% on Thursday and finished the week 1.5% higher at $14.51. They are down 45% over one month.

AstraZeneca said on Friday, September 11, after the U.S. close, that the Phase 3 SERENA-4 trial of camizestrant plus palbociclib in first-line advanced ER-positive breast cancer did not meet its primary progression-free-survival endpoint. Camizestrant already had U.S. accelerated approval, granted September 4, for tumors that develop an ESR1 mutation during first-line endocrine therapy. The miss was for a broader first-line use. AstraZeneca's ADR rose 3.7% this week.

The development-stage wrapper tracked that mix. The Virtus Biotech Clinical Trials ETF DBBC, which holds U.S.-listed biotechnology stocks with a lead drug still in the clinic, fell 1.6%. T. Rowe Price's new active biotech fund —TDNA began trading Thursday, September 17, and closed Friday at $24.97 on 205 shares; the $10.2 million is seed money.

Intuitive Surgical, CVS Health, and Medicaid's decade

BIHI gained 1.91%. Intuitive Surgical, a 14% position, rose 6.6% to $393.33 and supplied 0.91 percentage points, about half the fund's move. Dexcom and Edwards Lifesciences added the next 0.58. Intuitive is down 31% year to date. BIHI is down 16.4% in 2026 and sits 20% below its 52-week high.

BIHF fell 0.60%. CVS Health, a 13% sleeve, dropped 6.1% to $88.84 and subtracted 0.79 percentage points. Humana fell 5.8%. UnitedHealth, a 19% position, was slightly lower. Guardant Health and the lab companies Quest Diagnostics and Labcorp offset some of that. AXHS was little changed at +0.11% and remains the year's sleeper at +27.4%.

On Friday the White House said all 50 states, the District of Columbia, and Puerto Rico would receive most-favored-nation prices on selected Medicaid drugs, a model it said now covers 26 of the world's largest drugmakers and 90% of branded U.S. medicines. It put the savings at nearly $65 billion over ten years. The White House Council of Economic Advisers split that into $36.6 billion federal and $27.6 billion for states. Experts told the Associated Press the same day that the savings are unclear because the manufacturer deals are not public. Medicaid's net prescription-drug bill was $46 billion in fiscal 2024. Stretch the claimed $65 billion across a decade and it is about $6.5 billion a year, roughly 14% of that Medicaid drug bill, spread across 26 manufacturers. AXLV fell 0.25% that session. The announcement is a multi-year net-price question for the Lilly, Merck, and Johnson & Johnson book, not a one-week flow.

Owning AXLV is owning Lilly at 15% and ten names at 61%. This week's 1.83% was those names doing what a concentrated pharma-and-tools book does. The Twist week, the Xenon week, and Intuitive's 6.6% live in other funds, at other weights. The sector label is doing less work than the construction.